Biosency exports its new revolutionary technology that enables early detection of exacerbations in COPD

Biosency is revolutionizing the early detection of exacerbations in chronic obstructive pulmonary disease (COPD) with its advanced technology, the BVS3, integrated into the predictive digital medical device for telemonitoring, BORA Care®.

During the prestigious international conference of the American Thoracic Society (ATS 2023) held in Washington, D.C. on May 23rd, Yann Le Guillou, co-founder of Biosency, unveiled the results of their latest clinical study. These results highlight the ability of their BVS3 technology to predict acute COPD exacerbations using AI, on average 3 days before hospitalization in 86% of cases, with only 9% false positives. It should be noted that COPD is the third leading cause of mortality worldwide.

The medical community and patients will benefit from Biosency’s advanced technology. After demonstrating its effectiveness in France, Biosency is now targeting several countries such as Benelux, Germany, Poland, Italy, Spain, Portugal, Egypt, and India. Biosency’s international development is supported by the positive reception of its technology by healthcare professionals, as Biosency can demonstrate its positive impact on the management of COPD patients.

With 440 million COPD patients worldwide, there is a growing demand for innovative solutions in the field of respiratory health. By expanding into new markets, Biosency aims to become one of the leaders in respiratory telemonitoring innovation on a global scale.

Biosency’s revolutionary technology for early detection of COPD exacerbations opens up new prospects for patients with this chronic respiratory disease, as well as for other conditions such as pulmonary fibrosis. Through ongoing research and clinical work, as well as international development, Biosency aims to establish a leading position in this field and contribute to promoting French expertise in global health.

About Biosency

Biosency was created in July 2017 to address the lack of digital medical devices for the remote monitoring of patients suffering from chronic cardio-respiratory diseases, such as chronic obstructive pulmonary disease (COPD), the third leading cause of death in the world, affecting more than 392 million patients worldwide. In order to meet this challenge, Biosency has developed and markets Bora care®, a digital medical device (class 2a) for remote monitoring. This solution has already been adopted by over 160 French doctors. Based on cardio-respiratory data (SpO2, respiratory rate, heart rate) and the activity level measured, the BVS³ technology integrated into the platform makes it possible to visualise variations in patients’ vital signs via a predictive score and to alert health professionals when the score deteriorates so that they can adapt management and act in a targeted and preventive manner.

See Full Press Release at the Source: Biosency detects early COPD exacerbations thanks to Bora care®, a predictive digital medical device